The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Role of cholesterol metabolism in the pathogenesis of Alzheimerʼs disease
Abstract
PURPOSE OF REVIEW: Cholesterol has been shown to stimulate the cleavage of amyloid precursor protein (APP) into amyloid peptides involved in Alzheimer's disease. However, high level of peripheral cholesterol as a risk factor for Alzheimer's disease is still debated. This current review provides an update of the recent literature on cholesterol and APP metabolisms in the brain. RECENT FINDINGS: First, a new relationship between neuronal APP and cholesterol has been shown in which this protein controls cholesterol turnover required for neuronal activity. Second, oxysterols are able to stimulate the synthesis of ATP-binding cassette transporters involved in the exchange of amyloid peptides between the blood and the brain. Third, changes in APP targeting to lipid rafts and/or their composition in cholesterol regulate amyloid peptide production. SUMMARY: These recent findings open new areas of investigations to control the neuronal activity and to decrease the amyloid peptide levels in brain, opening on new preventive and therapeutic strategies for Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Altered cerebral cholesterol homeostasis may promote neurite pathology, Tau hyperphosphorylation, and the amyloidogenic pathway.
“Altered cerebral cholesterol homeostasis may promote neurite pathology, Tau hyperphosphorylation, and the amyloidogenic pathway [49].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [49]
Increased brain cholesterol levels and dyslipidemias overall have been linked to Alzheimer's disease incidence.
“Increased brain cholesterol levels and dyslipidemias overall have been linked to AD incidence [49,55,100,107].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [49]
Citations
Cites
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 1×
“Clearance of Ab is impaired in knock-in mice homozygous for the ApoE e4 genotype carrying familial mutated APP [5].”
BackgroundBlood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis
Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5390 · Cited by 267
Flagged first, then by citations
Research works printed but not linked: 23
- Selkoe, 2011, Cold Spring Harb Perspect Biol, 3, a004457, 10.1101/cshperspect.a004457 · DOI
- Cossec, 2010, Biochim Biophys Acta, 1801, 846, 10.1016/j.bbalip.2010.05.010 · DOI
- Marquer, 2011, FASEB J, 25, 1030, 10.1096/fj.10-168633 · DOI
- Popp, 2013, Biochem Pharmacol, 86, 37, 10.1016/j.bcp.2012.12.007 · DOI
- Saint-Pol, 2013, Brain Res, 1517, 1, 10.1016/j.brainres.2013.04.008 · DOI · Paper page
- Saint-Pol, 2014, J Alzheimers Dis, 30, 489, 10.3233/JAD-2012-112090 · DOI · Paper page
- Schweinzer, 2014, J Alzheimers Dis, 27, 341, 10.3233/JAD-2011-110854 · DOI
- Verghese, 2013, Proc Natl Acad Sci U S A, 110, E1807, 10.1073/pnas.1220484110 · DOI · Paper page
- Ghribi, 2006, J Neurochem, 99, 438, 10.1111/j.1471-4159.2006.04079.x · DOI · Paper page
- Saeed, 2014, J Lipid Res, 55, 313, 10.1194/jlr.P044982 · DOI
- Sagare, 2013, J Biol Chem, 288, 15154, 10.1074/jbc.M112.439570 · DOI
- Eckert, 2009, Neurobiol Dis, 35, 251, 10.1016/j.nbd.2009.05.005 · DOI
- Lazar, 2013, Acta Neuropathol, 125, 133, 10.1007/s00401-012-1041-1 · DOI
- Grimm, 2005, Nat Cell Biol, 7, 1118, 10.1038/ncb1313 · DOI
- Nomura, 2013, J Neurosci Res, 91, 1541, 10.1002/jnr.23278 · DOI
- Pierrot, 2013, EMBO Mol Med, 5, 608, 10.1002/emmm.201202215 · DOI
- Barbero-Camps, 2013, Hum Mol Genet, 22, 3460, 10.1093/hmg/ddt201 · DOI · Paper page
- Yao, 2012, J Exp Med, 209, 2501, 10.1084/jem.20121239 · DOI
- Hudry, 2010, Mol Ther, 18, 44, 10.1038/mt.2009.175 · DOI
- Urano, 2013, FASEB J, 27, 4305, 10.1096/fj.13-231456 · DOI
- Bhattacharyya, 2013, J Neurosci, 33, 11169, 10.1523/JNEUROSCI.4704-12.2013 · DOI · Paper page
- Marquet-de Rouge, 2013, Age (Dordr), 35, 1589
- Burg, 2013, J Neurosci, 33, 16072, 10.1523/JNEUROSCI.1506-13.2013 · DOI
Cited by
Sorted by citations
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“Aβ peptide is produced by the amyloidogenic pathway following the sequential proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-secretases [49].”
BackgroundWięckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Metadata
- Authors
- Allinquant, B., Clamagirand, C., & Potier, M.-C.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Allinquant, Bernadette
- Venue
- Current Opinion in Clinical Nutrition and Metabolic Care
- Published
- 2014-07
- Volume
- 17
- Issue
- 4
- Pages
- 319-323
- ISSN
- 1363-1950 (ISSN-L)
- OpenAlex
- W2328857389
- Cited by
- 47
- References
- 3
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 9 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 4 · 2015: 1 · 2014: 1
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Clinical Nutrition & Metabolic Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- cholesterol metabolism, Alzheimer's disease, amyloid precursor protein, oxysterols, ABC transporters, lipid rafts, blood-brain barrier
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Brain, Cholesterol, Disease Models, Animal, Humans, Neurons, Risk Factors, Amyloid beta-Protein Precursor, ATP-Binding Cassette Transporters, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
